Mesoblast Limited (AU:MSB) has released an update.
Mesoblast Limited, a leader in cellular medicines for inflammatory diseases, announced significant progress with their product Ryoncil, which is under FDA review for treating children with acute graft versus host disease (SR-aGVHD). The company has also made strides with its Phase 3 trial for chronic low back pain and is exploring an accelerated FDA approval pathway for Revascor in treating end-stage heart failure. Financially, Mesoblast has implemented a cost containment strategy, resulting in a reduced net operating cash spend and a solid cash balance as they prepare for Ryoncil’s potential commercial launch.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
